The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months.
Wang, Yu-Xiao; Tao, Hong; Hu, Jian-Li; Li, Jing-Xin; Dai, Wei-Ming; Sun, Jin-Fang; Liu, Pei; Tang, Jie; Liu, Wen-Yu; Zhu, Feng-Cai.
Expert Rev Vaccines
; 16(5): 515-524, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-28277801
Meningococcal vaccine A,C,W135,Y: conjugated to tetanus toxoid.
Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
Identification of antigen-specific B cell receptor sequences using public repertoire analysis.
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.
Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.
Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.
Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial.
[Evaluation of safety of meningococcal group AC bivalent polysaccharide conjugate vaccine in children aged 5-24 months old].